Halozyme Therapeutics reported $93.85M in EBITDA for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Acadia Pharmaceuticals ACAD:US $ -42.78M 23.1M
Agios Pharmaceuticals AGIO:US $ -88.87M 0.13M
Alnylam Pharmaceuticals ALNY:US $ -134.35M 39.3M
Amarin AMRN:US $ 9.56M 10.38M
Amgen AMGN:US $ 3188M 218M
Aptinyx Inc APTX:US $ -19766000 5.89M
Arena Pharmaceuticals ARNA:US $ -143.42M 12.4M
Baxter International BAX:US $ 698M 45M
Cara Therapeutics CARA:US $ -30815000 7.32M
Cytokinetics CYTK:US $ -54.25M 14.18M
Eli Lilly And LLY:US $ 1797.7M 218.8M
Esperion Therapeutics ESPR:US $ -32380000 50.29M
Halozyme Therapeutics HALO:US $ 93.85M 42.37M
Immunogen IMGN:US $ -26.83M 1.54M
Intercept Pharmaceuticals ICPT:US $ 1.39M 29.71M
Intra Cellular Therapies ITCI:US $ -69.02M 15.92M
JAZZ PHA JAZZ:US $ 77.72M 157.36M
Mannkind MNKD:US $ -8.02M 1.36M
Minerva Neurosciences NERV:US $ -8.96M 1.46M
Nektar Therapeutics NKTR:US $ -106.66M 0.81M
Peregrine Pharmaceuticals PPHM:US $ 7.94M 3.85M
Pfizer PFE:US $ 7593M 610M
Rigel Pharmaceuticals RIGL:US $ -12.79M 54.78M
United Therapeutics UTHR:US $ 234.6M 263.8M
Vanda Pharmaceuticals VNDA:US $ 13.08M 2.02M